# Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

> **NCT04569916** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** irinotecan liposome
- **DRUG:** apatinib
- **DRUG:** PD-1 antibody

## Key facts

- **NCT ID:** NCT04569916
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2023-02
- **Final completion:** 2023-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569916, "Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04569916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*